This site is intended for healthcare professionals only

New NICE guidelines recommend 'watch and wait' approach on prostate cancer

Written by: | Published:

New guidance on prostate cancer The new guidance could affect almost 8,000 of the 47,000 men diagnosed annually with the disease

New guidance from NICE on prostate cancer has recommended active surveillance for the first time, for men with the low-risk localised form of the disease. Previously men with such a diagnosis would have been offered a choice of a radical prostatectomy (to remove the gland and surrounding tissues) or radical radiotherapy – both of which come with distressing side effects but have been shown to cut the risks of the disease spreading to other areas of the body.

But new evidence presented by NICE has shown that active surveillance, the “watch and wait” approach of having regular blood tests and scans to see if the cancer develops, offers the same 10-year survival outcomes as the more radical treatments. The new guidance could affect almost 8,000 of the 47,000 men diagnosed annually with the disease.

Describing the development as ‘great news’, Heather Blake, director of support and influencing at the charity Prostate Cancer UK, said: ‘This could potentially provide thousands of men with the opportunity to safely delay or avoid radical treatment and its associated side effects.

‘What is crucial now is that active surveillance is consistently delivered to a high standard across the UK alongside the personalised information and support men need to confidently choose this approach and benefit from it for as long as possible.’

Dr Sam Merriel, GP and lead author of the new guidelines, stressed the need for ‘emotional and psychological support’ for men faced with the choice.

‘Despite the potential benefits for men, choosing active surveillance over radical treatment is not necessarily an easy decision as it goes against the natural instinct of wanting to get rid of the cancer immediately,’ he said.

Elsewhere the guidance recommended that all men suspected of having the disease should be offered an MRI scan before a biopsy. Professoe Mark Emberton, a prostate cancer specialist at University College London, described the decision as ‘a landmark’, saying: ‘The UK is the first country in the world to formally recommend MRI scans for prostate cancer.’

Prostate cancer remains the most common form of cancer in men, with 11,500 men dying of it every year. Approximately 400,000 men are living with or after the disease in the UK.

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.


This makes sense to me, as I have other health issues, and I feel that this will be less stressful than treatment potentially causing ongoing issues.
Posted by: ,

Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.